gaining competitive advantage in biotech patent research … biotech 2017 meeting book.pdf ·...

February 27 – 28, 2017 Embassy Suites Boston–Logan Airport Boston, MA

PIUG 2017 BIOTECHNOLOGY CONFERENCE

Gaining Competitive Advantage In Biotech Patent ResearchThrough Constructive Analysis And Client Engagement

Patent Information Users Group, Inc.

Meeting Book prepared by BizInt Solutions Inc., a proud sponsor of the 2017 PIUG Biotechnology Conference

7:00 am – 8:15 am Registration and Breakfast (exhibits open)

8:15 am – 8:25 am Welcome Remarks

8:25 am – 9:10 am Keynote - Global Filing Strategies for the Biotech/Pharmaceutical Patents Eugene Kim, Ironwood Pharmaceuticals

9:10 am – 9:40 am Quantifying EPO-Style Sequence Listings Thomas Marman, Pfizer Inc.

9:40 am – 9:50 am Product Reviews – BizInt, GQ Life Sciences

9:50 am – 10:20 am Break & Vendor Exhibits

10:20 am – 10:50 am The Constraint Potential of Biotechnology Patents and Determining When a Biosimilar Could Enter the Market Siobhan Palmer, QuintilesIMS

10:50 am – 11:20 am Biosimilars: Trends and Developments in the United States and Europe David Dunn, Clarivate Analytics

11:20 am – 11:30 am Product Reviews – ProQuest Dialog, Minesoft

11:30 am – 12:00 pm Challenges in Searching Biosimilar Sequences Julien Doudement, GQ Life Sciences

12:00 pm – 12:10 pm Product Reviews – STN, PatentSight

12:10pm – 1:40 pm Lunch & Vendor Exhibits

1:40 pm – 2:40 pm Open Space Discussion

2:40 pm – 3:10 pm Shining a Light into the Black Box of Patent Examination – the Nordic Approach Louise Boisen, Nordic Patent Institute

3:10 pm – 4:00 pm Break & Vendor Exhibits

4:00 pm – 4:30 pm Going beyond the Traditional Patent Search: The Use of Patent Metric Indicators To Assess Technological Advantage Greg Roland, Novartis Institute of Biomedical Research Holger Ernst, WHU- Otto Beisheim School of Management

4:30 pm – 5:00 pm The Role of Text Mining in Patent Research at Boehringer Ingelheim Thorsten Schweikardt, BI

5:00 pm – 5:30 pm Quality In, Quality Out – Innovation at Minesoft To Help with the “In”!! Robert Poolman, Minesoft

5:30 pm Closing Remarks

6:30 pm Networking dinner (registration required)

C O N F E R E N C E S C H E D U L E : T U E S D A Y , F E B R U A R Y 2 8 , 2 0 1 7

February 27 – 28, 2017 Embassy Suites Boston–Logan Airport Boston, MAPIUG 2017 BIOTECHNOLOGY CONFERENCE

2017 BIOTECHNOLOGY CONFERENCEFebruary 27-28, 2017 Embassy Suites Boston-Logan Airport Boston, Massachusetts

T A B L E O F C O N T E N T S

Message from the Chair ..............................................................2

Thank You to Sponsors ...............................................................3

Tuesday Morning Speakers .......................................................4

Tuesday Afternoon Speakers ................................................. 16

Sponsor Information ................................................................. 26

Workshops & Hotel Map .......................................................... 29

Attendees by Name .................................................................. 30

Attendees by Company ........................................................... 31

Please complete the evaluation survey for the conference at:

http://www.surveygizmo.com/s3/3346634/PIUG2017Biotech

PIUG 2017 Biotechnology Conference Boston, Massachusetts

Welcome to the PIUG 2017 Biotechnology Conference!

On behalf of the PIUG Board of Directors, I welcome you to the PIUG 2017 Biotechnology Conference. The organizing committee has an outstanding program for you. I hope you learn at least one new thing today. I also hope that you will take advantage of networking with your colleagues. I find that one of the most profitable aspects of PIUG. We also want to thank the sponsors of the meeting. Please stop by their booths and hear about their products and let them know how much we appreciate their support. Welcome to Boston 2017.

Martha Yates, PIUG Chair 2016-2018

The planning committee would like to welcome all attendees to the PIUG 2017 Biotechnology Conference. Now in its 11th year, the conference program has seen an evolution in the topics from “traditional” sequence searching to concepts such as biosimilars, text mining, analysis of “big” patent data, sequence listings, filing strategies, and the role of patent examiners. Our goal is for attendees to leave the conference with new techniques that they can apply to their daily job, and to connect attendees with vendors who have a common interest in patent searching.

Please visit the exhibit booths sponsored by BizInt, GQ Life Sciences, Proquest, Minesoft, STN, and PatentSight to get insights into their unique offerings. PIUG is a membership supported group always open to new ideas for meeting venues and topics. If you have not yet joined PIUG, please consider doing so to receive the many benefits of membership. Thank you for your attendance and supporting PIUG.

The Planning Committee

Welcome

2 PIUG 2017 Biotechnology Conference Boston, Massachusetts

gratefully acknowledges the generous support

provided by our sponsors. The meeting would not exist

without their support!

Platinum SponsorsBizInt Solutions

GQ Life Sciences

Silver SponsorsMinesoft

PatentSightProQuest Dialog

STN

Bronze SponsorsQuintilesIMS

3PIUG 2017 Biotechnology Conference Boston, Massachusetts

Global Filing Strategies for the Biotech/Pharmaceutical PatentsEugene Kim, Ironwood Pharmaceuticals

8:25– 9:10 am

ABSTRACT

Global filing strategies for protecting biotechnological and pharmaceutical discoveries requires

the careful consideration of a multitude of factors, including cost, overall IP budget, local laws,

market size, enforceability of the patents, to name but a few. In addition, such filings need to be

closely coordinated with ongoing development, clinical, manufacturing and regulatory activities.

In this presentation, I will review these factors in close detail, with particular focus on protecting

therapeutic products and, wherever possible, provide recommendations for companies of different

stages/sizes.

BIOGRAPHY

Gene is Senior Intellectual Property Counsel at Ironwood Pharmaceuticals. He has experience

working at biotech and pharmaceutical companies ranging from early-stage startups to global

pharmaceutical companies, protecting and evaluating IP on a broad range of technologies and

molecules, ranging from biological and small molecule therapeutics, gene and oligonucleotide

therapies, and microbiomes. Prior to joining Ironwood, Gene worked at Pfizer, Indigo Agriculture,

Synageva BioPharma, Alnylam Pharmaceuticals and Biogen. Gene received his Ph.D. in Biology from

the University of Pennsylvania, and his J.D. from the Suffolk University Law School.

M O R N I N G S P E A K E R S


Global Filing Strategies for the Biotech/Pharmaceutical Patents Eugene Kim, Ironwood Pharmaceuticals


Quantifying EPO-Style Sequence ListingsThomas Marman, Pfizer Inc.

9:10 – 9:40 am

ABSTRACT

The format of amino acid sequence listings varies between the European Patent Office (EPO)

and the United States Patent & Trademark Office (USPTO). There are distinct differences in the

presentation of alternative or variable amino acids in sequences (e.g., when the residue at a given

position could be alanine or glycine). The EPO requires selection of one of the amino acids in the

group to be represented in the sequence, while other offices, such as the USPTO, require the use of

Xaa to represent these alternative amino acids. This presentation aims to discuss the prevalence of

these EPO-style sequence listings in sequence databases. In order to investigate and quantify these

types of sequences, the annotation/feature tables must be heavily replied upon, since the sequence

alone is not useful in the identification. The majority of the statistics presented here are based on

the freely available sequence data set at EBI-EMBL produced by the EPO. This data set was queried

using Python scripts, which provide more flexibility in the type of queries and fields that can be

searched when compared to most commercial databases.

BIOGRAPHY

Tom is currently in Pfizer’s Patent Searching & Information group and has been a small molecule

patent searcher at both Pfizer and Wyeth for a combined 12 years. Prior experience includes an

additional 4 years searching as a Senior R&D Information Scientist at Dow Chemical after many

years as a bench chemist at ANGUS Chemical, a small specialty chemicals company. He has a Ph.D.

in Organic Chemistry from Texas A&M University and a B.S. in Chemistry from the University of

Connecticut.



Quantifying EPO-Style Sequence Listings Thomas Marman, Pfizer Inc.


The Constraint Potential of Biotechnology Patents and Determining When a Biosimilar Could Enter the MarketSiobhan Palmer, QuintilesIMS

10:20 – 10:50 am

ABSTRACT

Patent thickets around a biologic molecule can make it hard for a patent analyst to determine which

patents are truly protective and prevent the entry of a biosimilar onto the market, and those which

could be circumvented. As many as 20 key patent families could relate to the biologic molecule,

but in reality, a maximum of 5 are likely to be genuine blockers. This challenge is even larger when

considering variability of protection in different geographies. In this session we will explore how

the proprietary constraint analysis of the QuintilesIMS Ark Patent Intelligence database can be used

to compare the expiry dates of these patents, and alongside data/marketing exclusivity, be used

to identify a date at which probable biosimilar entry can be achieved. We will also use examples to

explore strategies which have been employed to protect biologics by Innovators such as Amgen,

who have managed to prolong the protection of Neulasta® (pegfilgrastim) using patents that

protect manufacturing processes rather than the product itself.

BIOGRAPHY

Siobhán Palmer has a BSc in Chemistry from the University of Surrey. Siobhan joined QuintilesIMS,

previously IMS Health, 8 years ago as a patent analyst for IMS Health’s Patent Focus database.

Siobhan’s current role is as Product Manager for the Ark Patent Intelligence database.



The Constraint Potential of Biotechnology Patents and Determining When a Biosimilar Could Enter the Market Siobhan Palmer, QuintilesIMS


Biosimilars: Trends and Developments in the United States and EuropeDavid Dunn, Clarivate Analytics

10:50 – 11:20 am

ABSTRACT

Biosimilars are an emerging competitive force within the biopharmaceuticals industry. Blockbuster

biologics have lost patent and market exclusivity in major markets including the US and Europe. Major

firms such as Sandoz, Amgen and Hospira (Pfizer) have launched biosimilars in Europe and the US and they

have more products in the late stages of development and approval. Thomson Reuters will review the

current pipeline of biosimilars and how they directly or indirectly threaten branded products. We will look

at the challenges of bringing these products to market and how innovators and biosimilars developers are

applying strategies to influence the landscape in their favor.

BIOGRAPHY

David Dunn is US Practice Lead and Scientific Advisor in the Portfolio and Licensing Services group at

Clarivate Analytics. He has over 20 years of experience in the pharmaceutical industry and advises clients

on management and optimization of their research and commercial portfolios.



Biosimilars: Trends and Developments in the United States and Europe David Dunn, Clarivate Analytics


Challenges in Searching Biosimilar SequencesJulien Doudement, GQ Life Sciences

11:30 am – 12:00 pm

ABSTRACT

Biosimilar monoclonal antibodies present many challenges for information retrieval. What does

similar really mean and what are the consequences when searching patents? Examples of recent

biosimilars on the market will be reviewed to highlight the oncoming obstacles for researchers and

patent searchers.

BIOGRAPHY

Julien Doudement is a Product Manager at GQ Life Sciences. He advises customers on patent search

best practices, while advancing new product features and content delivery. With 10 years at the

company, he combines extensive biological research experience with a deep understanding of

the GQ platform. Previously at Servier Laboratories, he immersed himself in the daily application

of information technology to biological problems in drug discovery. He holds Master Degrees in

Biology and Bioinformatics.



Challenges in Searching Biosimilar Sequences Julien Doudement, GQ Life Sciences


RE-INVENT THE USER EXPERIENCE

APPLY TODAY AND RECEIVEBETA ACCESS!

contact us: +1 844-841-3059 or visit gqlifesciences.com


GQ-PAT GROWTH

LAST2

YEARS


Open Space Discussion

1:40 – 2:40 pm

PROPOSED TOPICS:

» Searcher Certification

» Co-occurring Biotech + Northeast meeting

» New tools or Road-maps from Vendors

» Suggestions and feedback for search products

» Current challenges and trends in biotech searching, for example:

» target searches

» diagnostics

» devices

» wearable devices

» The role of patent competitive intelligence

» Other suggestions from audience

A F T E R N O O N S P E A K E R S


Open Space Discussion


Shining a Light into the Black Box of Patent Examination – the Nordic ApproachLouise Boisen, Nordic Patent Institute

2:40 – 3:10 pm

ABSTRACT

Gain an insight into practical patent examination and the thought processes of an examiner and use

this insight when evaluating the relevance of prior art in your own searches. In this presentation you will

be introduced to the daily life of an examiner from the Nordic Patent Institute (NPI). I will illustrate how

the examiners at NPI work and, in particular, how we think when considering novelty and obviousness.

A key part of the process involves a dialogue between applicant and examiner prior to search. The

dialogue serves to accurately determine the essence of the invention and identify fallback positions

not necessarily apparent from the initial claims. Tailoring the search accordingly, the examiner can thus

provide the applicant with the information necessary for adapting the application for further progress

around the world.

BIOGRAPHY

Louise Boisen has worked as a patent examiner at the Nordic Patent Institute (NPI) and the Danish

Patent and Trademark Office (DKPTO) since January 2014. Apart from searching and examining

national and PCT patent applications, she also delivers IP services to businesses throughout the world.

In addition, Louise is responsible for implementing best practice procedures and developing new

services for the commercial search service units of both NPI and DKPTO. Louise has a background in

recombinant antibody technology with a Ph.D. from the University of Aarhus, Denmark, and did her

postdoctoral training at Warwick Medical School, Coventry, UK.



Shining a Light into the Black Box of Patent Examination – the Nordic Approach Louise Boisen, Nordic Patent Institute


Going beyond the Traditional Patent Search – The Use of Patent Metric Indicators To Assess Technological AdvantageGreg Roland, Novartis Institute of Biomedical Research and Holger Ernst, WHU – Otto Beisheim School of Management

4:00 – 4:30 pm

ABSTRACT

The traditional patent search for determining FTO or patentability involves the use of multiple

resources to take advantage of value-added indexing or searcher developed free-text strategy. Once

a set of references has been identified, the results are typically summarized to bring to the attention

of the practitioner relevant aspects of the identified references as they pertain the query. The

searcher is often asked to rank results by relevance, date, number of family members or those with

dominating claims. This is a subjective exercise representing a snapshot in time but does not display

trends or allows for a comprehensive view with a reliable and objective method. New methods

to review patent search results are now available as a way to assess the competitive advantage of

assignee’s portfolio. Early efforts to establish rankings were based on quantitative or qualitative

assessments that lacked global coverage or relied on statistical correlations to patent maintenance

rates. The use of empirical indicators such as Market Coverage™, Technology Relevance™,

Competitive Impact™ and the Patent Asset Index™ can establish a reliable and objective numerical

value of an individual patent family or an organization’s entire portfolio. In this presentation these

empirical indicators developed by PatentSight will be used to analyse the clustered regularly

interspaced short palindromic repeats (CRISPR) area, a method to edit or delete existing genes,

as a method to assess the technological position of an organization, its innovativeness as well as

sustainable competitive advantage.

BIOGRAPHIES

Holger Ernst is full professor of business administration, esp. technology and innovation

management at the WHU - Otto Beisheim School of Management, Vallendar, Germany. Prof. Ernst’s

research interests lie in the fields of strategy, innovation, commercialization of technologies, new

product development and intellectual property. Prof. Ernst is co-founder of PatentSight, located in

Bonn, Germany, that specializes in the development and selling of software products and consulting

services in the field of business intelligence based on patent data.

Greg Roland is currently the Global Head of Search and Analytics within the patent department at

the Novartis Institutes of BioMedical Research (NIBR) located in Cambridge, MA. Greg has 26 years

of experience in the pharmaceutical industry and searching the patent literature and competitor

pipeline databases.



Going beyond the Traditional Patent Search: The Use of Patent Metric Indicators To Assess Technological Advantage Greg Roland, Novartis Institute of Biomedical Research and Holger Ernst, WHU – Otto Beisheim School of Management


The Role of Text Mining in Patent Research at Boehringer IngelheimThorsten Schweikardt, BI

4:30 – 5:00 pm

ABSTRACT

Scientists can spend a lot of their time separating patents relevant to a specific question from

non-significant ones. We have developed a patent analysis workflow to prioritize the patents

being reviewed in order to save the scientist’s time and cut costs by using text mining and other

techniques. We will explain that process and the benefits derived from it. The optimal prioritization

criteria can be defined freely for each project, making the workflow very flexible to use. We describe

the general workflow using text mining and pipelining tools like Linguamatics I2E and KNIME, and

take a look at challenges and possible future enhancements.

BIOGRAPHY

Thorsten is a Senior Information Scientist at the Scientific Information Center of Boehringer

Ingelheim Pharma located in Biberach, Germany. He provides project support for early-to-late stage

projects in RD&M with database research, information retrieval and text mining. He is a structural

biologist by training and holds a Ph.D. from the University of Mainz, Germany.



The Role of Text Mining in Patent Research at Boehringer Ingelheim Thorsten Schweikardt, BI


Quality In, Quality Out – Innovation at Minesoft To Help with the “In”!!Robert Poolman, Minesoft

5:00 – 5:30 pm

ABSTRACT

The quality of any search stems from the comprehensiveness of a search strategy. Although no

database can do the search for you, it can provide features and functionality to help. Delivered from

the perspective of an experienced biotech patent analyst, we will use case studies to discuss the

challenges in ensuring comprehensiveness and the features and functionality of PatBase which can

help, including: (1) PatBase Thesaurus to help identify synonyms, acronyms, names and numbers

(2) PatBase Semantic searching to broaden any patent search (3) Non-patent literature searching in

PatBase to identify relevant prior art (4) The ability to link to relevant information including sequence

information, clinical trial data and FDA OrangeBook information. This presentation will demonstrate

how any user can benefit from the innovative features and functionality in PatBase to craft a

meaningful patent analysis.

BIOGRAPHY

Rob is currently a Senior Manager (Innovation and Consulting) at Minesoft Ltd, UK. In 2000, and

having completed a Ph.D. in Biochemistry, Rob started his career at Pfizer as a Biotechnology

Information Consultant providing biomedical, patent and competitive intelligence to both research

scientists and patent attorneys. During 6 years at Pfizer, he helped form and lead a high-performing

team of information professionals within the Legal division. In 2006, he joined Novartis to create and

manage the NIBR Search and Analytics team and during the last 3 years at Novartis, Rob completed

an M.B.A. at Warwick Business School which allowed him to take on additional operational and

managerial responsibilities. With over 15 years of experience in the information industry, Rob

has recently joined Minesoft to spearhead their future product development, to enhance their

consultancy based approach and to bring an end user perspective to the company.



Quality In, Quality Out – Innovation at Minesoft To Help with the “In”!! Robert Poolman, Minesoft


Platinum SponsorsBIZINT SOLUTIONS, INC.

BizInt Smart Charts software helps information analysts create, customize and distribute competitive intelligence

reports and visualizations from drug pipeline, clinical trial, patent and gene sequence databases. The BizInt Smart

Charts product family is used by pharmaceutical, biotech, chemical and device/diagnostics companies worldwide to

support product lifecycle planning and portfolio management.

GQ LIFE SCIENCES

GQ Life Sciences an Aptean company enables life science companies to search worldwide patent literature for

DNA and other biological sequences. Its database, GQ-Pat, is the largest repository of such patented sequences. IP

professionals and law firms use GenomeQuest to perform freedom to operate, patentability, and prior art searches.

GenomeQuest serves 18 of the top 20 pharmaceutical companies and all five top agrochemical companies, with a

customer base of nearly 200 leading life sciences organizations.


chemical explorerExtract essential chemical information from full textpatents with Chemical Explorer

• Perform a chemical structure search against FULL TEXT• Instantly retrieve compounds occurring throughout the document• Patent documents publishing in English language, German, French, Japanese, Chinese and Korean

Chemical Explorer, TextMine and PatBase: a unique, powerful combination to instantly identify and review the exact location of the chemical compound in the full text of patent documents as never before

www.minesoft.com/chemical-structure-searching

R&D STRATEGY

TRENDS

M&A

BENCHMARKING

LICENSING

PORTFOLIO MGMT

AN ANALYTICS PLATFORM CREATED FOR STRATEGIC IP MANAGEMENT

PatentSight offers an unparalleled patentanalytics platform enabling you to take thequality of patents into account using thePatent Asset Index™.

6 of the top 10 chemical companies in theworld use PatentSight for their IP strategydevelopment and portfolio managementneeds.

A PLATFORM BUILT TO DRIVE DECISIVEACTION

WWW.PATENTSIGHT.COM


CONTENT.POWER.RELIABILITY.

PRECISE SEARCHING FOR PROFESSIONALS

www.stn.orgFor more information, visit the STN booth today!

When it comes to searching, trust the experts. STN is the most complete search and retrieval platform for the world’s disclosed scientifi c and technical research. Only STN off ers CAS REGISTRYSM and other authoritative databases, Thomson Reuters’ Derwent World Patents Index®, and the most complete off ering of science and technical content along with unparalleled search precision. The world’s patent offi ces rely on STN, shouldn’t you?



Monday, Feb 27 Workshop

10:00 am – 12:00 pm PIUG-Sponsored PresentationSearching Biotechnological Inventions under the EPC Dr. Klaus-Peter Dopfer, EPO

1:00 pm – 2:00 pm Creating IP Sequence Reports with BizInt Smart Charts: Tips & TricksJohn Willmore

2:30 pm – 3:30 pm GQ Life Sciences: UpdatesJulien Doudement

4:00 pm – 5:00 pm Minesoft: The Latest Solutions From Minesoft Rob Poolman

C O N F E R E N C E W O R K S H O P S

Baldwin, Christopher ...........................PatentSight Barrett, Dianah ........................................PfizerBoisen, Louise..........................................Nordic Patent InstituteBrown, Jim ................................................FIZ KarlsruheButler, Barbara .........................................SanofiCawley, Dillon ..........................................AbbottChiu, George ............................................Johnson & JohnsonDanko, Anthony .....................................ProQuestDe Greef, Sarah .......................................darts-ipDoepfer, Klaus-Peter ............................European Patent OfficeDoudement, Julien ...............................GQ Life SciencesDunn, David .............................................Clarivate AnalyticsEberle, Matt ..............................................BizInt SolutionsEichelman, Cynthia ...............................LinguamaticsErnst, Holger ............................................PatentSight Faerman, Carlos ...................................... IndependentFisher, Donna ........................................... IPSEN BioscienceGore Willse, Ann ....................................Boehringer IngelheimHampton, Barbara.................................RedLine Information ServicesHumel Denton, Alice ...........................CASJiang, Ning ................................................PfizerKim, Eugene ............................................. Ironwood PharmaceuticalsKocis, Helena ...........................................Kratunis, John ..........................................CASLeBeau, Susan .........................................LinguamaticsLeung, Benjamin ....................................Global Prior ArtLim, Jimmy ...............................................Panasonic CorporationMarman, Thomas ..................................PfizerMendelson, Seth ....................................EisaiMeng, Qin .................................................Bright Information GroupMiller, Nicholas ........................................ ipanMiller, Barbara..........................................NovartisOstanock, Phillip ....................................MinesoftPalmer, Siobhan .....................................QuintilesIMSPatankar, Gargee ....................................Gridlogics TechnologiesPerkins, Bill ................................................GQ Life SciencesPoolman, Robert....................................MinesoftReeve, Mary Jane ...................................GlaxoSmithKlineRobins, Suzanne ....................................Patent Information ServicesRoland, Greg ............................................NovartisRopke, Ken ................................................MinesoftSandvoss, Leah .......................................PfizerSchweikardt, Thorsten ........................Boehringer IngelheimShanker, Sumana ...................................Shire PharmaceuticalsTaylor, Alison ............................................Abbott

Trippe, Anthony .....................................PatinformaticsTurner, Elyse .............................................Tzimas, Maritsa .......................................GlaxoSmithKlineWeiss-Nolen, Monica ...........................SanofiWillmore, John ........................................BizInt SolutionsWu, Danyu ................................................GQ Life SciencesYates, Martha ...........................................Monsanto CompanyYuan, Qiong .............................................CAS

A T T E N D E E S B Y N A M E


Abbott ........................................................Dillon CawleyAbbott ........................................................Alison TaylorBizInt Solutions .......................................Matt EberleBizInt Solutions .......................................John WillmoreBoehringer Ingelheim .........................Ann Gore WillseBoehringer Ingelheim .........................Thorsten SchweikardtBright Information Group ..................Qin MengCAS ...............................................................Alice Humel DentonCAS ...............................................................John KratunisCAS ...............................................................Qiong YuanClarivate Analytics .................................David Dunndarts-ip .......................................................Sarah De GreefEisai ..............................................................Seth MendelsonEuropean Patent Office ......................Klaus-Peter DoepferFIZ Karlsruhe ............................................Jim BrownGlaxoSmithKline.....................................Mary Jane ReeveGlaxoSmithKline.....................................Maritsa TzimasGlobal Prior Art .......................................Benjamin LeungGQ Life Sciences ....................................Julien DoudementGQ Life Sciences ....................................Bill PerkinsGQ Life Sciences ....................................Danyu WuGridlogics Technologies ....................Gargee PatankarIndependent............................................Carlos Faermanipan ..............................................................Nicholas MillerIPSEN Bioscience ....................................Donna FisherIronwood Pharmaceuticals...............Eugene KimJohnson & Johnson..............................George ChiuLinguamatics ...........................................Cynthia EichelmanLinguamatics ...........................................Susan LeBeauMinesoft.....................................................Phillip OstanockMinesoft.....................................................Robert PoolmanMinesoft.....................................................Ken RopkeMonsanto Company ............................Martha YatesNordic Patent Institute ........................Louise BoisenNovartis ......................................................Barbara MillerNovartis ......................................................Greg RolandPanasonic Corporation .......................Jimmy LimPatent Information Services .............Suzanne RobinsPatentSight ..............................................Christopher BaldwinPatentSight ..............................................Holger ErnstPatinformatics .........................................Anthony TrippePfizer ............................................................Dianah BarrettPfizer ............................................................Ning JiangPfizer ............................................................Thomas MarmanPfizer ............................................................Leah Sandvoss

ProQuest ....................................................Anthony DankoQuintilesIMS .............................................Siobhan PalmerRedLine Information Services .........Barbara HamptonSanofi ..........................................................Barbara ButlerSanofi ..........................................................Monica Weiss-NolenShire Pharmaceuticals .........................Sumana Shanker

A T T E N D E E S B Y C O M P A N Y



The Patent Information Users Group, Inc. (PIUG) – The International Society for Patent Information Professionals is a not-for-profit organization for individuals having a professional, scientific or technical interest in patent information. The mission of PIUG is to support, assist, improve and enhance the success of patent information professionals through leadership, education, communication, advocacy and networking. Through this international forum and discussion, we also promote and improve the retrieval, analysis and dissemination of patent information.

PIUG has over 500 active members representing 24 countries including the United States. The largest concentration of members is from the USA, Europe and India. PIUG members are patent attorneys, patent agents, licensing professionals, patent information researchers, patent information vendors, and patent information and documentation experts from the U.S. and abroad.

We have nearly 300 patent information professionals who do patent searching for corporations, over 100 patent information consultants, over 80 patent information professionals who do patent searching for law firms, and about 12 searchers based in academic institutions. We are employed in performing patentability, freedom-to-practice, and validity patent searches for Fortune 500 / multinational companies, leading universities and major IP law firms. In recent years, PIUG members have also engaged in patent information analysis as a strategic innovation tool.

PIUG has an active Discussion Forum that is featured on the PIUG wiki, a global collaborative tool with over 1800 subscribers worldwide. In addition, we have presence in professional and social networking channels, such as LinkedIn and Twitter. Get to know us and meet the PIUG Officers.

BRIEF HISTORY

The Patent Information Users Group (PIUG) was established in 1988. The objective of the group was to create a forum to discuss issues and concerns relevant to the patent searcher community. PIUG promotes the importance of intellectual property, especially patent publications, and most specifically, the computerized patent databases. Since 1988, PIUG has worked with intellectual property database producers and vendors to maintain and to improve the quality of their product from the customer, or user, perspective. Please see the PIUG History page for much more information about PIUG.

MEMBERSHIP INFORMATION

Membership is based on the calendar year. Renewals after October 1 are effective until December 31 of the following year. The one-year membership fee is $95 (US). The discounted annual membership fee is $50 (US) and is available for full-time students, full-time retirees, individuals unemployed at the time of renewal, and individuals residing in an emerging country as defined by PIUG as low, lower middle or upper middle income countries on the World Bank’s World Bank List of Economies spreadsheet.

For a list of membership benefits please visit our website: www.piug.org/membership

PATENT INFORMATION USERS GROUP, INC.

The International Society for Patent Information Professionals

SAVE THESE DATES!

• PIUG Membership Directory (Members-Only Site)• Members-only access to Conference Proceedings

(Annual, Biotech, and Northeast Conferences)• Access to PIUG Salary Surveys• Discounts for World Patent Information, Pharmaceutical Patent

Analyst & JSTOR

• Quarterly e-Newsletter & Access to Archives• Enhanced functionality on PIUG Wiki• Ongoing professional training through conferences and

workshops• Access to PIUG LinkedIn group

ATTENDEE COMMENTS FROM A PREVIOUS PIUG CONFERENCE:“It is a great opportunity to talk with peers, get new ideas and be reminded of the essentials. I thoroughly enjoy the conference.”

“My first PIUG annual meeting and overall it was a great experience. As a first time attendee and speaker, I was initially intimidated, but so many of the “regulars”

were open and welcoming, it was actually less stressful than I expected. The first timer’s meeting was a blast, due in part to the great volunteers. I’m looking

forward to attending next year now that I know better what to expect.”

“Excellent…speakers from variety of industry and background”

“PIUG has certainly helped me a great deal in search

and analysis for my projects”

“Timely training on current TECHNIQUES and TOOLS”

Patent Information Users Group, Inc. • 40 E.Main Street, #1438 • Newark,DE 19711Phone: (302) 660-3275 • Email: [email protected] • www.piug.org

PIUG 2017ANNUAL CONFERENCEThe Complete 21 st Century Patent Searcher – Addressing Our Skills Gap

MAY 20 - 25Crowne Plaza Atlanta Perimeter at Ravinia, Atlanta, GA

PIUG 2017NORTHEAST CONFERENCESEPTEMBER 25 – 27APA Hotel Woodbridge, Iselin, NJ

KEY MEMBER BENEFITS

UPCOMING PIUG COURSEPatent Searching Fundamentals

MARCH 22–23, 2017Global Intellectual Property Academy (GIPA), USPTO, Alexandria, VA

KEYNOTE SPEAKERNICHOLAS BELKIN

Distinguished Professor of Information Science, Department of Library & Information Science,

School of Communication & Information, Rutgers University

Are you using the best tools and ingredients?

www.bizint.com

We’ve moved!We’ve relocated our office to the beautiful state of Washington in the Pacific Northwest.

SEATTLE

WAS H I N G TO

N

Come talk with us in the Exhibit Hall.

Contact us at [email protected] for a demonstration or free trial.

• Integrate timely data and unique content from each source.

• Quickly create reports combining sequence and IP data.

• Select and summarize data based on your database rankings and rules.

• New in Version 4: support for new STN; new fields in PatBase, Orbit, GenomeQuest; new Summary Record export.

gaining competitive advantage in biotech patent research … biotech 2017 meeting book.pdf ·...

Documents